Current Price | $1.34 | Mkt Cap | $235.0M |
---|---|---|---|
Open | $1.36 | P/E Ratio | -9.28 |
Prev. Close | $1.34 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $1.31 - $1.36 | Volume | 243 |
52-Wk Range | $0.71 - $1.96 | Avg. Daily Vol. | 1,108,325 |
The Company is a clinical-stage drug development company that discovers and develops novel, small molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases.
Current Price | $1.34 | Mkt Cap | $235.0M |
---|---|---|---|
Open | $1.36 | P/E Ratio | -9.28 |
Prev. Close | $1.34 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $1.31 - $1.36 | Volume | 243 |
52-Wk Range | $0.71 - $1.96 | Avg. Daily Vol. | 1,108,325 |
The best Bull and Bear pitches based on recency and number of recommendations.
Obviously this puts them in a tough spot with Fostamatinib but they do have a few bullets left to fire in 2013 along with some cash that was raised at the end of 2012. I think the offering priced at 9.50. Not saying I have much of a valuation model… More
I simply used the screener to identify 1-star companies with the highest 52-week gain. The 1-star rating should mean they are bad companies and the 52-week gain should mean they are overpriced. We’ll see how it works!
Read the most recent pitches from players about RIGL.
Recs
FDA approval of a new cancer drug MONTHS ahead of schedule. This is the first time in my life I have heard of this. It went on sale in Q4 of 2022, at a price of something crazy like $33,000 per year. They just started another drug trial. I think this makes them a takeover target. They were at risk of delisting when the FDA approval announcement came out. They were around $0.63 per share then, and were being piled on by shorts. They made the 10+ days in a row above $1 per share, and now trade about 100% above that 52 week low. Although still on shaky ground in the worst stock market in 14 years, RIGL looks to be making a strong base above $1/sh and headed higher in 2023. Adding shares in Roth, Traditional IRA, and Calls in non qualified account. 1 year average analyst price target is above $3/share.
Recs
COVID trials
Recs
indication for their approved drug.
Find the members with the highest scoring picks in RIGL.
qubit15 (27.50) Score: +621.51
The Score Leader is the player with the highest score across all their picks in RIGL.
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
---|---|---|---|---|---|---|---|---|---|---|
qubit15 | 27.50 | 1/21/2009 | NS | $6.95 | -80.72% | +540.79% | +621.51 | 0 Comment | ||
robo2011 | 21.95 | 11/17/2008 | NS | $6.53 | -79.48% | +509.12% | +588.60 | 0 Comment | ||
anticitradeshort | 30.04 | 4/20/2009 | NS | $6.43 | -79.16% | +505.80% | +584.96 | 0 Comment | ||
cybob2000 | 53.27 | 10/23/2008 | 3W | $15.64 | -91.43% | +482.76% | +574.19 | 0 Comment | ||
schwah8 | 97.89 | 10/13/2008 | NS | $18.26 | -92.66% | +456.95% | +549.61 | 0 Comment | ||
EV38biotech | < 20 | 11/5/2008 | 5Y | $8.60 | -84.42% | +434.71% | +519.13 | 0 Comment | ||
Mynx828 | 69.77 | 9/17/2009 | 5Y | $7.45 | -82.01% | +380.84% | +462.85 | 0 Comment | ||
longtermgrowth09 | 67.37 | 12/17/2009 | 5Y | $8.97 | -85.06% | +363.20% | +448.27 | 0 Comment | ||
darksider389 | 82.77 | 7/7/2008 | 3M | $21.97 | -93.90% | +325.03% | +418.93 | 0 Comment | ||
flats66 | 64.25 |
|
3Y | $22.71 | -94.10% | +313.83% | +407.93 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.